Journals / Anatomy / 2017 / Cilt: 11 - Sayı: 3

Standardization of sternocleidomastoid for botulinum toxin applications

Journal
Anatomy
Pages
128–132
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In one male cadaver, colored latex was injected according to the results ofthe measurements.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives:Botulinum toxin is frequently applied to the sternocleidomastoid muscle (SCM) for torticollis treatment.
📊
Key Findings & Data:Results: The respective mean width of upper, medial and lower segments were 33.15 (23–41) mm, 36.45 (28–45) mm and,39.35 (15–50) mm, respectively.
💡
Conclusion & Impact:In one male cadaver, colored latex was injected according to the results ofthe measurements.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives:Botulinum toxin is frequently applied to the sternocleidomastoid muscle (SCM) for torticollis treatment. Duringthis application, bulb of the jugular vein located under SCM makes the interventions unsafe. Also, injecting the botulinumtoxin into the infrahyoid muscles which lie under SCM may cause hoarseness and swallowing disorders. The aim of this studywas to describe the most reliable and appropriate botulinum toxin injection sites to the SCM to avoid injury to neighboringneurovascular structures and adjacent muscles. Methods: In ten male cadavers, SCM was evaluated in three equal segments (upper, middle and lower). Muscle width and thickness at the center of each segment were measured. In one male cadaver, colored latex was injected according to the results ofthe measurements. Results: The respective mean width of upper, medial and lower segments were 33.15 (23–41) mm, 36.45 (28–45) mm and,39.35 (15–50) mm, respectively. The mean thickness of upper, medial and lower segments were 5.29 (3.87–7.68) mm, 5.89(3.56–8.32) mm and 3.60 (0.69–7.75) mm, respectively. There was no significant difference between the right and left sides.The thickest part of the muscle was the middle part, and the lower part was the thinnest. When the colored latex injected cadaver was dissected, the center of the muscle was observed as colored, while the neighboring structures were avoided. The thickest and safest part of SCM for the botulinum toxin injections was the middle part. Conclusion:Knowing the thickness of SCM will make the botulinum toxin applications to this muscle safer and easier

🔖

Cite This Article

TORUN, B. İ., KENDİR, S., UZ, A. (2017). Standardization of sternocleidomastoid for botulinum toxin applications. Anatomy, Cilt: 11 - Sayı: 3, 128–132. https://ajindex.com/articles/146133

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hanagasi HA. Cervical dystonia and botulinum toxin treatment. Nöropsikiyatri Arflivi 2006;43:27–30
  2. Tomczak KK, Rosman NP. Torticollis. J Child Neurol 2013;28:365– 78
  3. Bledsoe IO, Comella CL. Botulinum toxin treatment of cervical dystonia. Semin Neurol 2016;36:47–53
  4. Bhidayasiri R. Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 2011;17:S20–4
  5. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12:392–9
  6. Scott AB. The role of botulinum toxin type A in the management of strabismus. In: Scientific and therapeutic aspects of botulinum toxin. Brin MF, Hallett M, Jankovic J, editors. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. p. 189–95
  7. Comella CL. Cervical dystonia: treatment with botulinum toxin serotype A as Botox or Dysport. In: Scientific and therapeutic aspects of botulinum toxin. Brin MF, Hallett M, Jankovic J, editors. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. p. 359– 364
  8. Blitzer A, Zalvan C, Gonzalez-Yanez O, Brin MF. Botulinum toxin type A injections for the management of the hyperfunctional larynx. In: Brin MF, Hallet M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. p.207–16
  9. Brin MF, Binder W, Blitzer A. Botulinum toxin type A BOTOX for pain and headache. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. p. 233–50
  10. Schwartz MFB. Botulinum toxin A therapy for temporomandibular disorders. In: Brin MF, Hallett M, and Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. p. 259
  11. Tintner RJJ. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In: Brin MF, Hallett M, and Jankovic J, Editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia (PA): Lippincott Williams and Wilkins; p. 343–50
  12. Stephan S, Wang TD. Botulinum toxin: clinical techniques, applications, and complications. Facial Plast Surg 2011;27:529–39
  13. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscop